Molecular Basis of AmpC Hyperproduction in Clinical Isolates of Escherichia coli
- 1 April 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (4) , 957-959
- https://doi.org/10.1128/aac.43.4.957
Abstract
DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.Keywords
This publication has 20 references indexed in Scilit:
- Cloning of AAC(3) and AAD(2″) genes fromAcinetobacter: differential expression in the host strainCurrent Microbiology, 1991
- The stability of E. coli gene transcripts is dependent on determinants localized to specific mRNA segmentsCell, 1986
- TRANSCRIPTION TERMINATION AND THE REGULATION OF GENE EXPRESSIONAnnual Review of Biochemistry, 1986
- beta-Lactamases and beta-lactam resistance in Escherichia coliAntimicrobial Agents and Chemotherapy, 1985
- Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectorsGene, 1985
- Selection and characterization of beta-lactam-resistant Escherichia coli K-12 mutantsAntimicrobial Agents and Chemotherapy, 1983
- Insertion of IS2 creates a novel ampC promoter in Escherichia coliCell, 1983
- Recombination between short DNA homologies causes tandem duplicationNature, 1981
- The E. coli β-lactamase attenuator mediates growth rate-dependent regulationNature, 1981
- Beta-lactam resistance in clinical isolates of Escherichia coli caused by elevated production of the ampC-mediated chromosomal beta-lactamaseAntimicrobial Agents and Chemotherapy, 1979